Common Diseases in Clinical Cohorts — Not Always What They Seem
Fedik Rahimov(AbbVie (United States)), Nizar Smaoui(AbbVie (United States)), Benjamin M. Jacobs(Queen Mary University of London), Ammar J. Alsheikh(AbbVie (United States)), Mark Reppell(AbbVie (United States)), Valerie Pivorunas(AbbVie (United States)), Andrew Blumenfeld(COPE Health Solutions), Heath Guay(AbbVie (United States)), Howard J. Jacob(Medical College of Wisconsin), Stephen Sawcer(University of Cambridge), Jeffrey F. Waring(AbbVie (United States)), John S. Lee(PhaseBio Pharmaceuticals (United States)), Naim Al Mahi(University of Cincinnati), Haukur J. Sigurðsson(GeneFluidics (United States)), Ali Abbasi(Shahroud University of Medical Sciences)
Cited by 15
Related Papers
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
|Nature|2011|2.8k
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
|Nature Genetics|2013|1.5k
Complex genetic signatures in immune cells underlie autoimmunity and inform therapy
|Nature Genetics|2020|1.3k
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
|Brain|2009|962
Multiple Sclerosis Severity Score
|Neurology|2005|959